Michael Gilman
InvestorDr. at Novartis Venture Fund
About
Michael Gilman, PhD, is a scientist, general manager, biotech executive and entrepreneur. He founded and led Padlock Therapeutics (acquired by Bristol-Myers Squibb in 2016) and Stromedix (acquired by Biogen Idec), and held senior research and pipeline roles at Biogen Idec and ARIAD Pharmaceuticals. Earlier he was on the scientific staff at Cold Spring Harbor Laboratory; he holds a PhD in Biochemistry from UC Berkeley and an SB in Life Science from MIT.
Invests in
Biotech
Investments
Board seats
Arrakis TherapeuticsObsidian TherapeuticsScholar RockX4 Pharmaceuticals
Per the firm's website.
Colleagues at Novartis Venture Fund
Aaron Nelson
Managing Director at Novartis Venture Fund
Adam Cotton
Principal at Novartis Venture Fund
Anja Koenig
Global Head of NVF at Novartis Venture Fund
Anja König
Global Head at Novartis Venture Fund
Bart Dzikowski
Managing Director, Head of Transactions & Legal at Novartis Venture Fund
Beat Steffen
Managing Director at Novartis Venture Fund
Christoph Meier
Investor at Novartis Venture Fund
Elaine Jones
Investor at Novartis Venture Fund
Frequently asked questions
- Who is Michael Gilman?
- Michael Gilman, PhD, is a scientist, general manager, biotech executive and entrepreneur. He founded and led Padlock Therapeutics (acquired by Bristol-Myers Squibb in 2016) and Stromedix (acquired by Biogen Idec), and held senior research and pipeline roles at Biogen Idec and ARIAD Pharmaceuticals. Earlier he was on the scientific staff at Cold Spring Harbor Laboratory; he holds a PhD in Biochemistry from UC Berkeley and an SB in Life Science from MIT.
- Where does Michael Gilman work?
- Michael Gilman is Dr. at Novartis Venture Fund.
- What does Michael Gilman invest in?
- Michael Gilman invests in Biotech.
- What boards does Michael Gilman sit on?
- Michael Gilman holds tracked board seats at Arrakis Therapeutics, Obsidian Therapeutics, Scholar Rock, X4 Pharmaceuticals.